Pu Jiangtao, Teng Zhangyu, Zhang Tao, Wang Biao, Zhang Dengguo, Yang Qin, Yang Qiao, Sun Xingwang, Long Wenbo
Departments of Thoracic Surgery.
Pathology, Affiliated Hospital of Southwest Medical University, Sichuan, China.
Appl Immunohistochem Mol Morphol. 2023 Mar 1;31(3):189-195. doi: 10.1097/PAI.0000000000001100. Epub 2023 Feb 6.
Molecular markers in the prognosis of esophageal squamous cell carcinoma (ESCC) patients who received postoperative treatments are lacking. This research aims to evaluate the prognostic value of polyadenylate-binding protein cytoplasmic 1 (PABPC1) alone and in combination with RAD51 in ESCC patients who underwent postoperative chemotherapy (CT). A total of 103 ESCC patients who underwent postoperative CT and 103 matched ones who received surgery alone were analyzed in this study. PABPC1 and RAD51 expression was assessed in cancer samples by immunohistochemistry. PABPC1 high expression (PABPC1-HE) but not that of RAD51 was associated with poor patients' survival, regardless of the postoperative treatment or node status. Patients with PABPC1 low expression and RAD51 negative expression [RAD51- (PABPC1-LE/RAD51-)] tumor had good overall survival (OS) in both the CT treated and untreated groups. Patients with PABPC1-LE/RAD51+ and PABPC1-HE/RAD51+ tumors had longer OS in the CT treated group than in the untreated group. However, PABPC1-HE/RAD51- was associated with a poor outcome in both groups and the patients with PABPC1-HE/RAD51- tumor had hardly any benefit from CT in N+ status. PABPC1 alone and in combination with RAD51 was a prognostic biomarker for OS in ESCC patients who received postoperative CT.
接受术后治疗的食管鳞状细胞癌（ESCC）患者缺乏分子标志物。本研究旨在评估聚腺苷酸结合蛋白胞质1（PABPC1）单独及与RAD51联合在接受术后化疗（CT）的ESCC患者中的预后价值。本研究共分析了103例接受术后CT的ESCC患者和103例仅接受手术的匹配患者。通过免疫组织化学评估癌组织样本中PABPC1和RAD51的表达。无论术后治疗或淋巴结状态如何，PABPC1高表达（PABPC1-HE）而非RAD51高表达与患者预后不良相关。PABPC1低表达且RAD51阴性表达[RAD51-（PABPC1-LE/RAD51-）]肿瘤的患者在CT治疗组和未治疗组中均具有良好的总生存期（OS）。PABPC1-LE/RAD51+和PABPC1-HE/RAD51+肿瘤的患者在CT治疗组中的OS比未治疗组更长。然而，PABPC1-HE/RAD51-在两组中均与不良预后相关，且PABPC1-HE/RAD51-肿瘤的患者在N+状态下几乎无法从CT中获益。PABPC1单独及与RAD51联合是接受术后CT的ESCC患者OS的预后生物标志物。
